Ai Iwauchi, Nei Fukasawa, Jun Takei, Miku Maeda, Kyoichi Tomoto, Akihiko Teshigawara, Yohei Yamamoto, Yasuharu Akasaki, Yuzuru Hasegawa, Yuichi Murayama, Keisuke Miyake, Masayuki Shimoda, Toshihide Tanaka
{"title":"新诊断胶质母细胞瘤贝伐单抗新辅助治疗前后红细胞转化特异性-1相关基因表达的比较分析","authors":"Ai Iwauchi, Nei Fukasawa, Jun Takei, Miku Maeda, Kyoichi Tomoto, Akihiko Teshigawara, Yohei Yamamoto, Yasuharu Akasaki, Yuzuru Hasegawa, Yuichi Murayama, Keisuke Miyake, Masayuki Shimoda, Toshihide Tanaka","doi":"10.62347/GQWP4029","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of the present study was to investigate the expression of erythroblast transformation specific-1 related gene (ERG) in patients with glioblastoma (GB) before and after bevacizumab (Bev) therapy as a predictive and prognostic biomarker.</p><p><strong>Methods: </strong>The present study used 58 GB tissues from 29 patients in 3 settings. Sixteen tumors were removed after neoadjuvant Bev administration (neoBev) and 13 represented newly diagnosed GB without previous Bev treatment (naïve Bev). Another 29 specimens of recurrence were obtained from salvage surgery or autopsy.</p><p><strong>Results: </strong>Immunohistochemical analysis showed both vessel density (VD) and ERG score were decreased in neoBev compared with naïve Bev. VD and ERG score tended to be lower at recurrence than at initial surgery (P=0.0026 and P=0.1338, respectively). In the naïve Bev and neoBev cohorts, overall survival (OS) with high and low expressions of ERG was comparable (P=0.7516 and P=0.3862, respectively).</p><p><strong>Conclusion: </strong>High expression of ERG in GB with naïveBev was significantly reduced with Bev, but not changed in refractoriness. Stratification of ERG expression levels might provide a useful predictive biomarker for GB treated with Bev.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558313/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparative analyses of erythroblast transformation specific-1 related gene expression before and after neoadjuvant bevacizumab therapy for newly diagnosed glioblastoma.\",\"authors\":\"Ai Iwauchi, Nei Fukasawa, Jun Takei, Miku Maeda, Kyoichi Tomoto, Akihiko Teshigawara, Yohei Yamamoto, Yasuharu Akasaki, Yuzuru Hasegawa, Yuichi Murayama, Keisuke Miyake, Masayuki Shimoda, Toshihide Tanaka\",\"doi\":\"10.62347/GQWP4029\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The aim of the present study was to investigate the expression of erythroblast transformation specific-1 related gene (ERG) in patients with glioblastoma (GB) before and after bevacizumab (Bev) therapy as a predictive and prognostic biomarker.</p><p><strong>Methods: </strong>The present study used 58 GB tissues from 29 patients in 3 settings. Sixteen tumors were removed after neoadjuvant Bev administration (neoBev) and 13 represented newly diagnosed GB without previous Bev treatment (naïve Bev). Another 29 specimens of recurrence were obtained from salvage surgery or autopsy.</p><p><strong>Results: </strong>Immunohistochemical analysis showed both vessel density (VD) and ERG score were decreased in neoBev compared with naïve Bev. VD and ERG score tended to be lower at recurrence than at initial surgery (P=0.0026 and P=0.1338, respectively). In the naïve Bev and neoBev cohorts, overall survival (OS) with high and low expressions of ERG was comparable (P=0.7516 and P=0.3862, respectively).</p><p><strong>Conclusion: </strong>High expression of ERG in GB with naïveBev was significantly reduced with Bev, but not changed in refractoriness. Stratification of ERG expression levels might provide a useful predictive biomarker for GB treated with Bev.</p>\",\"PeriodicalId\":13943,\"journal\":{\"name\":\"International journal of clinical and experimental pathology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558313/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of clinical and experimental pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.62347/GQWP4029\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical and experimental pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/GQWP4029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Comparative analyses of erythroblast transformation specific-1 related gene expression before and after neoadjuvant bevacizumab therapy for newly diagnosed glioblastoma.
Objective: The aim of the present study was to investigate the expression of erythroblast transformation specific-1 related gene (ERG) in patients with glioblastoma (GB) before and after bevacizumab (Bev) therapy as a predictive and prognostic biomarker.
Methods: The present study used 58 GB tissues from 29 patients in 3 settings. Sixteen tumors were removed after neoadjuvant Bev administration (neoBev) and 13 represented newly diagnosed GB without previous Bev treatment (naïve Bev). Another 29 specimens of recurrence were obtained from salvage surgery or autopsy.
Results: Immunohistochemical analysis showed both vessel density (VD) and ERG score were decreased in neoBev compared with naïve Bev. VD and ERG score tended to be lower at recurrence than at initial surgery (P=0.0026 and P=0.1338, respectively). In the naïve Bev and neoBev cohorts, overall survival (OS) with high and low expressions of ERG was comparable (P=0.7516 and P=0.3862, respectively).
Conclusion: High expression of ERG in GB with naïveBev was significantly reduced with Bev, but not changed in refractoriness. Stratification of ERG expression levels might provide a useful predictive biomarker for GB treated with Bev.
期刊介绍：
The International Journal of Clinical and Experimental Pathology (IJCEP, ISSN 1936-2625) is a peer reviewed, open access online journal. It was founded in 2008 by an international group of academic pathologists and scientists who are devoted to the scientific exploration of human disease and the rapid dissemination of original data. Unlike most other open access online journals, IJCEP will keep all the traditional features of paper print that we are all familiar with, such as continuous volume and issue numbers, as well as continuous page numbers to keep our warm feelings towards an academic journal. Unlike most other open access online journals, IJCEP will keep all the traditional features of paper print that we are all familiar with, such as continuous volume and issue numbers, as well as continuous page numbers to keep our warm feelings towards an academic journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
